The American Liver Foundation (ALF) has announced the eight winners of its 2024 Pilot Research Awards, with four of the awards going to scientist-led…
News
Precision Biosciences has opened a first-in-human trial testing its gene-editing therapy candidate PBGENE-HBV in people with chronic hepatitis B infections, and says data…
CHOLANGITIS
NewsIqirvo to treat PBC approved for public funding in England and Wales
England’s National Institute for Health and Care Excellence (NICE) has recommended that Iqirvo (elafibranor) be covered by the country’s National Health Service (NHS)…
CHOLESTASIS
NewsPFIC caused by USP53 usually mild form of liver disease: Study
Progressive familial intrahepatic cholestasis (PFIC) caused by mutations in the USP53 gene results in a fairly mild form of the disease, with most of…
FATTY LIVER DISEASE
NewsSagimet planning Phase 3 trials of denifanstat in MASH, MASLD
Sagimet Biosciences is planning the launch of two Phase 3 clinical trials to test its oral therapy candidate denifanstat in people with fatty…
ALAGILLE SYNDROME
NewsSoftware helps ID hard-to-interpret Alagille-causing gene mutations
Software tools may help predict whether certain hard-to-interpret mutations in the JAG1 gene affect splicing, a process that can direct how a protein is produced,…
The U.S. Food and Drug Administration (FDA) has cleared the launch of a Phase 1 drug-drug interaction study to evaluate the effects of certain drugs…
CHOLANGITIS
NewsRTY-694 chosen as lead treatment candidate for liver disease PSC
Rectify Pharmaceuticals has selected the oral small molecule RTY-694 as its lead treatment candidate for primary sclerosing cholangitis (PSC) and plans are underway…
CHOLESTASIS
NewsEarly-onset pregnancy cholestasis increases risk of diabetes: Study
Women diagnosed with intrahepatic cholestasis of pregnancy (ICP) before 24 weeks of gestation, or about six months, are significantly more likely to develop gestational…
FATTY LIVER DISEASE
NewsStudy fully enrolled of Rezdiffra for well-compensated liver cirrhosis
A Phase 3 clinical trial testing Rezdiffra (resmetirom) in people with well-compensated cirrhosis, or irreversible liver scarring that still allows the liver to work, due…
Recent Posts
- Living with MASH reminds me to avoid making assumptions
- Particles in grilled meats may trigger liver disease, mouse study finds
- Supporting my oldest son, who’s growing up with a chronically ill sibling
- Human trial testing gene silencing injection therapy for MASH kicks off
- Blood bile acids predict liver outcomes in Alagille syndrome children: Study